Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H21N3O2S.C4H6O4 |
Molecular Weight | 413.488 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1
InChI
InChIKey=PORMUFZNYQJOEI-UHFFFAOYSA-N
InChI=1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
Molecular Formula | C4H6O4 |
Molecular Weight | 118.088 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H21N3O2S |
Molecular Weight | 295.4 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8568822 |
330.0 nM [IC50] | ||
Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9871581 |
38.3 nM [EC50] | ||
Target ID: CHEMBL1805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11708905 |
35.0 nM [EC50] | ||
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14643336 |
5.3 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date1997 |
|||
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date1997 |
|||
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
49 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
90 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
112 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
144 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
29 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
80 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
194 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
158 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
380 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
44 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
476 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
590 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
105 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
239 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / month multiple, oral Dose: 200 mg, 1 times / month Route: oral Route: multiple Dose: 200 mg, 1 times / month Sources: |
unhealthy, 18 - 65 years n = 94 Health Status: unhealthy Condition: acute migraine with aura Age Group: 18 - 65 years Sex: M+F Population Size: 94 Sources: |
|
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: (SUMATRIPTAN) Sources: 12 mg subcutaneous injections |
unhealthy, 35 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 35 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: |
6 mg 2 times / day multiple, subcutaneous Overdose Dose: 6 mg, 2 times / day Route: subcutaneous Route: multiple Dose: 6 mg, 2 times / day Sources: |
unhealthy, 36 years n = 1 Health Status: unhealthy Condition: episodic cluster headache Age Group: 36 years Sex: M Population Size: 1 Sources: |
|
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Other AEs: Abnormal physical sensation, Abnormal physical sensation... Other AEs: Abnormal physical sensation (6%) Sources: Abnormal physical sensation (6%) Abnormal physical sensation (6%) Sensation of pressure (8%) Chest tightness of (2%) Throat tightness (3%) Pain (1%) Pressure (3%) Vertigo (2%) Malaise and fatigue (3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | 1 patient Disc. AE |
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: (SUMATRIPTAN) Sources: 12 mg subcutaneous injections |
unhealthy, 35 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 35 years Sex: F Population Size: 1 Sources: |
Pain | 1% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Chest tightness of | 2% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Vertigo | 2% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Malaise and fatigue | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Pressure | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Throat tightness | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Sensation of pressure | 8% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
weak | ||||
yes [IC50 6.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | weak (co-administration study) Comment: coadministered with clarithromycin: mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/12017403/ |
|||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
An unusual case of renal vein thrombosis in a man taking sumatriptan. | 1999 Jun |
|
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. | 1999 Mar 5 |
|
Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. | 1999 May |
|
Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. | 1999 Sep |
|
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. | 2000 Nov |
|
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. | 2001 |
|
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. | 2001 |
|
A clinical trial on a plate? The potential of 384-well format solid phase extraction for high-throughput bioanalysis using liquid chromatography/tandem mass spectrometry. | 2001 |
|
Cluster headache: review of the literature. | 2001 Apr |
|
[Current topics: expectation for new triptans]. | 2001 Apr 10 |
|
[Migraine: sumatriptan]. | 2001 Apr 10 |
|
[Migraine: selection of therapeutic agents to be applied during its attack]. | 2001 Apr 10 |
|
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. | 2001 Aug |
|
Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. | 2001 Feb |
|
A systematic review of the use of triptans in acute migraine. | 2001 Feb |
|
[Treatment of cluster headache]. | 2001 Feb |
|
[Cluster headache--clinical aspects, pathophysiology and treatment]. | 2001 Feb 20 |
|
Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. | 2001 Jan |
|
[First manifestation of migraine as acute confusional state: "confusional migraine" and diagnostic problems]. | 2001 Jan-Feb |
|
Effect of rizatriptan in the spectrum of headache. | 2001 Jun |
|
Sumatriptan can alleviate headaches due to carotid artery dissection. | 2001 Jun |
|
[Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist]. | 2001 Jun |
|
Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. | 2001 Jun |
|
Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. | 2001 Jun 13 |
|
Relaxation induced by serotonin and sumatriptan in isolated guinea pig gallbladder strips. | 2001 Mar |
|
Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. | 2001 Mar |
|
The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype. | 2001 Mar |
|
Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation. | 2001 Mar |
|
Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. | 2001 Mar 6 |
|
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. | 2001 May |
|
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. | 2001 May |
|
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. | 2001 May 1 |
|
Modifications by sumatriptan and acetylcholine of nitric oxide-mediated neurogenic dilatation in dog cerebral arteries. | 2001 May 18 |
Sample Use Guides
Migraine Headache. Oral: 25 mg, 50 mg, or 100 mg PO (taken with fluids); Not to exceed 100 mg/dose; additional doses q2hr PRN. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hr; Not to exceed 12 mg SC q24hr
Cluster Headache. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hour; Not to exceed 12 mg SC q24hr
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26659468
The uptake of sumatriptan and other triptans via OCT1 and OCT3 was characterized using HEK293 cells stably transfected to overexpress wild-type OCT1 or OCT3. For measuring the uptake in human hepatocytes, was used cryopreserved human hepatocytes (Gibco Life Technologies, Darmstadt, Germany) obtained from a single donor with two fully active OCT1 alleles. Triptan uptake in OCT1 and OCT3-overexpressing HEK293 cells was measured by incubating the cells with varying concentrations of the substrates in 12-well plates for two minutes at pH 7.4 and 378C. The reaction was stopped with ice-cold buffer, the cells were lysed with 80% acetonitrile, and the intracellularly accumulated triptans were quantified by liquid chromatography coupled to tandem massspectrometry.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:12:39 GMT 2023
by
admin
on
Fri Dec 15 15:12:39 GMT 2023
|
Record UNII |
J8BDZ68989
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
SUMATRIPTAN GALPHARM (REFUSED: MIGRAINE DISORDERS)
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001003
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
67158
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
59772
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
DTXSID60145966
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
SUB15437MIG
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
100000077527
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
1642201
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
AA-44
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
J8BDZ68989
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
J8BDZ68989
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
C29470
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
103628-48-4
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
m10396
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
64359
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
760362
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL128
Created by
admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Calculate the percentage of sumatriptan related compound A free base in the portion of sumatriptan free base taken
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |